Cashu
Clear Street Enhances Biotechnology Research Focus, Highlighting Enliven Therapeutics' Investment Potential
about 1 year ago
Stocks
Health Care
elvn
Enliven Therapeutics
NASDAQ: ELVN
+2.74 (+11.78%)
25.99
USD
At close at Jan 09, 21:43 UTC
Overview
Loading chart...
Key Stats
Market Cap
1.38B
Dividend Yield
0.00%
P/E Ratio
-14.17
EPS
-1.89
Revenue
-
Avg. Volume
2.34M
About
What does ELVN do?
Enliven Therapeutics, a clinical stage precision oncology company based in Boulder, Colorado, went public on March 12, 2020. It is developing ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 mutations.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.